UK Standards for Microbiology Investigations

X and V Factor Test
Acknowledgments

UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see https://www.gov.uk/government/groups/standards-for-microbiology-investigations-steering-committee).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the Medical Editors for editing the medical content.

For further information please contact us at:

Standards Unit
Microbiology Services
Public Health England
61 Colindale Avenue
London NW9 5EQ
E-mail: standards@phe.gov.uk

Website: https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories

UK Standards for Microbiology Investigations are produced in association with:

Logos correct at time of publishing.
**Amendment Table**

Each SMI method has an individual record of amendments. The current amendments are listed on this page. The amendment history is available from standards@phe.gov.uk.

New or revised documents should be controlled within the laboratory in accordance with the local quality management system.

<table>
<thead>
<tr>
<th>Amendment No/Date.</th>
<th>8/08.01.15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issue no. discarded.</td>
<td>2.5</td>
</tr>
<tr>
<td>Insert Issue no.</td>
<td>3</td>
</tr>
<tr>
<td><strong>Section(s) involved</strong></td>
<td><strong>Amendment</strong></td>
</tr>
<tr>
<td>Whole document.</td>
<td>Hyperlinks updated to gov.uk.</td>
</tr>
<tr>
<td>Page 2.</td>
<td>Updated logos added.</td>
</tr>
<tr>
<td>Scope of the document.</td>
<td>More information was added to the scope of the document.</td>
</tr>
<tr>
<td>Introduction.</td>
<td>This section has been updated and references added.</td>
</tr>
<tr>
<td>Technical information/Limitations.</td>
<td>This section has been updated.</td>
</tr>
<tr>
<td>Safety Considerations.</td>
<td>Information and references updated.</td>
</tr>
<tr>
<td>Reagents/Equipment.</td>
<td>This section has been updated.</td>
</tr>
<tr>
<td>Quality Control Organisms.</td>
<td>For this test, <em>Haemophilus haemoglobinophilus</em> NCTC 8540 is used for the X factor only. The quality control organisms have been validated by NCTC.</td>
</tr>
<tr>
<td>Procedures and Results.</td>
<td>Information and references updated</td>
</tr>
<tr>
<td>Flowchart.</td>
<td>This flowchart has been updated for easy guidance.</td>
</tr>
<tr>
<td>References.</td>
<td>Some references updated.</td>
</tr>
</tbody>
</table>
UK Standards for Microbiology Investigations#: Scope and Purpose

Users of SMIs

- SMIs are primarily intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the UK.
- SMIs provide clinicians with information about the available test repertoire and the standard of laboratory services they should expect for the investigation of infection in their patients, as well as providing information that aids the electronic ordering of appropriate tests.
- SMIs provide commissioners of healthcare services with the appropriateness and standard of microbiology investigations they should be seeking as part of the clinical and public health care package for their population.

Background to SMIs

SMIs comprise a collection of recommended algorithms and procedures covering all stages of the investigative process in microbiology from the pre-analytical (clinical syndrome) stage to the analytical (laboratory testing) and post-analytical (result interpretation and reporting) stages.

Syndromic algorithms are supported by more detailed documents containing advice on the investigation of specific diseases and infections. Guidance notes cover the clinical background, differential diagnosis, and appropriate investigation of particular clinical conditions. Quality guidance notes describe laboratory processes which underpin quality, for example assay validation.

Standardisation of the diagnostic process through the application of SMIs helps to assure the equivalence of investigation strategies in different laboratories across the UK and is essential for public health surveillance, research and development activities.

Equal Partnership Working

SMIs are developed in equal partnership with PHE, NHS, Royal College of Pathologists and professional societies.

The list of participating societies may be found at [https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories](https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories). Inclusion of a logo in an SMI indicates participation of the society in equal partnership and support for the objectives and process of preparing SMIs. Nominees of professional societies are members of the Steering Committee and Working Groups which develop SMIs. The views of nominees cannot be rigorously representative of the members of their nominating organisations nor the corporate views of their organisations. Nominees act as a conduit for two way reporting and dialogue. Representative views are sought through the consultation process.

SMIs are developed, reviewed and updated through a wide consultation process.

---

SMIs are predominantly used in clinical microbiology and the two GMC-recognised specialties of Medical Microbiology (which includes Bacteriology, Mycology and Parasitology) and Medical Virology.

Microbiology is used as a generic term to include the two GMC-recognised specialties of Medical Microbiology (which includes Bacteriology, Mycology and Parasitology) and Medical Virology.
Quality Assurance
NICE has accredited the process used by the SMI Working Groups to produce SMIs. The accreditation is applicable to all guidance produced since October 2009. The process for the development of SMIs is certified to ISO 9001:2008.

SMIs represent a good standard of practice to which all clinical and public health microbiology laboratories in the UK are expected to work. SMIs are NICE accredited and represent neither minimum standards of practice nor the highest level of complex laboratory investigation possible. In using SMIs, laboratories should take account of local requirements and undertake additional investigations where appropriate. SMIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. SMIs also provide a reference point for method development.

The performance of SMIs depends on competent staff and appropriate quality reagents and equipment. Laboratories should ensure that all commercial and in-house tests have been validated and shown to be fit for purpose. Laboratories should participate in external quality assessment schemes and undertake relevant internal quality control procedures.

Patient and Public Involvement
The SMI Working Groups are committed to patient and public involvement in the development of SMIs. By involving the public, health professionals, scientists and voluntary organisations the resulting SMI will be robust and meet the needs of the user. An opportunity is given to members of the public to contribute to consultations through our open access website.

Information Governance and Equality
PHE is a Caldicott compliant organisation. It seeks to take every possible precaution to prevent unauthorised disclosure of patient details and to ensure that patient-related records are kept under secure conditions.

The development of SMIs are subject to PHE Equality objectives https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity. The SMI Working Groups are committed to achieving the equality objectives by effective consultation with members of the public, partners, stakeholders and specialist interest groups.

Legal Statement
Whilst every care has been taken in the preparation of SMIs, PHE and any supporting organisation, shall, to the greatest extent possible under any applicable law, exclude liability for all losses, costs, claims, damages or expenses arising out of or connected with the use of an SMI or any information contained therein. If alterations are made to an SMI, it must be made clear where and by whom such changes have been made.

The evidence base and microbial taxonomy for the SMI is as complete as possible at the time of issue. Any omissions and new material will be considered at the next review. These standards can only be superseded by revisions of the standard, legislative action, or by NICE accredited guidance.

SMIs are Crown copyright which should be acknowledged where appropriate.
**Scope of Document**

This UK Standard for Microbiology Investigation (SMI) describes the differentiation of *Haemophilus* species by the X and V test. Because similarities exist in growth factor requirements of *Haemophilus* species, in critical situations, it is not recommended that this procedure be the sole criterion for species identification.

This SMI should be used in conjunction with other SMIs.

**Introduction**

Species of the genus *Haemophilus* require either or both of two factors X and V for growth and can be used to differentiate the species. Both factors are present in blood.

X factor comprises protoporphyrin IX, also called haemin or other iron-containing porphyrins. These are required for growth because X-dependent strains are unable to convert d-aminolaevulinic acid to protoporphyrin. They are heat stable.

V factor comprises nicotinamide adenine dinucleotide (NAD) or nicotinamide adenine dinucleotide phosphate (NADP). They are heat labile.

The factors are incorporated in filter paper discs which are placed on a blood free medium previously inoculated with the organism under test. After incubation, the presence or absence of growth around the discs is recorded. The presence of growth around the disc but not elsewhere on the plate indicates a requirement for that particular factor.

**Technical Information/Limitations**

**Erroneous results**

V factor diffuses more readily than X factor. If the discs are placed too close together, V factor may diffuse towards the X factor disc, leading to growth apparently due to X factor rather than V.

**Commercial Identification Kits**

Commercial manufacturers of X and V factor discs do not specify the concentration of the factors. Acceptance of a batch of discs should be based on an ‘in use’ performance test with a range of *Haemophilus* species rather than an assay of content.

Each batch or shipment of XV Factor discs should be checked with a positive control, and the X Factor and V Factor discs are tested with both known positive and negative controls before routine use in the laboratory to ensure quality control.

**Agar Media**

The use of chocolate agar is more preferable for X and V factor testing rather than blood agar or blood containing medium because of risk of carryover of X factor. This test could also be done using a basic nutrient agar but for which the X and V discs have been validated in case it had trace factors that could influence the results, usually identifying *H. influenzae* as *H. parainfluenzae*.

Manufacturers' instructions should be followed when performing this test.
More accurate results are obtained with the porphyrin synthesis test (TP 29 – Porphyrin Test).

The swab used for setting up the plate for X and V factors can also be used for setting up antibiotic plates as long as the X and V factors are set up first.

**Incubation**

The X and V factor tests could sometimes give false V dependent results if incubated in CO₂².

**Issues with the HACEK group of organisms (apart from Haemophilus species)**

*Eikenella corrodens* are X-dependent as they exhibit growth around the X disc when tested, which is a useful diagnostic test. The other organisms may be X and V-dependent or may require only either X or V factor¹.
1 Safety Considerations

*Haemophilus influenzae* is a Hazard Group 2 organism, and, in some cases the nature of the work may dictate full Containment Level 3 conditions. All laboratories should handle specimens as if potentially high risk.

*H. influenzae* can cause serious invasive disease, especially in young children. Invasive disease is usually caused by encapsulated strains of the organism.

Laboratory acquired infections have been reported. The organism infects primarily by the respiratory route (inhalation), autoinoculation or ingestion in laboratory workers.

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet. For the urease test, a urea slope is considered safer than a liquid medium. The use of needles, syringes, or other sharp objects should be strictly limited and eye protection must be used where there is a known or potential risk of exposure to splashes.

Refer to current guidance on the safe handling of all organisms and reagents documented in this SMI.

The above guidance should be supplemented with local COSHH and risk assessments.

Compliance with postal and transport regulations is essential.

2 Reagents and Equipment

Discrete bacterial colonies growing on solid medium
Normal saline or distilled water
Sterile swabs
Test agar plate as recommended by manufacturers’ instructions
Commercially available discs impregnated with X, V and XV factors
Bacteriological straight wire/loop or disposable alternative

3 Quality Control Organisms

**X and V factor**
*Haemophilus influenzae* NCTC 11931

**V factor only**
*Haemophilus parainfluenzae* NCTC 10665

**X factor only**
*Haemophilus haemoglobinophilus* NCTC 8540

*Note:* These strains have been validated by NCTC to give this result.
4 Procedure and Results

4.1 X and V Factor Test Method\textsuperscript{1,2}

- Make a light suspension of the test organism by touching one or more morphologically similar colonies with a straight wire and emulsifying in normal saline or distilled water.
- Soak a swab in the suspension and spread evenly across the entire surface of a test agar plate. This allows for maximum growth.
- Allow a few minutes for agar surface to dry.
- Place X, V and XV discs on the agar surface in area of inoculum. Ensure the discs are a minimum of 1 cm apart in an equilateral triangle configuration (to prevent diffusion from the discs giving false results) or follow manufacturer’s instructions.
- Gently press down on discs so that they adhere to agar surface.
- Incubate in 3-5% CO\textsubscript{2} at 35-37°C overnight.
- Examine the plates in a good light source for growth around the discs and interpret the test agar plates according to the table below.

\begin{itemize}
  \item [H. influenzae] (Growth around XV disc only)
  \item [H. parainfluenzae] (Growth around V and XV discs)
\end{itemize}

**Interpretation**

Organisms that require only X Factor will grow only in the area of the X and XV Factor discs. Organisms that require only V Factor will grow only in the areas of the V and the XV Factor discs. If both X and V Factors are required, the organism will grow only in the area of the XV Factor disc.

Below is a summary of X, V and XV Factor results.

<table>
<thead>
<tr>
<th>Haemophilus species</th>
<th>Growth around discs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X</td>
</tr>
<tr>
<td>H. influenzae</td>
<td>-</td>
</tr>
<tr>
<td>H. parainfluenzae</td>
<td>-</td>
</tr>
<tr>
<td>H. haemoglobinophilus</td>
<td>+</td>
</tr>
<tr>
<td>H. aegyptius\textsuperscript{*}</td>
<td>-</td>
</tr>
</tbody>
</table>
### X and V Factor Test

<table>
<thead>
<tr>
<th>Bacterium</th>
<th>X</th>
<th>V</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>H. haemolyticus</em></td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td><em>H. pittmaniae</em></td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><em>H. parahaemolyticus</em></td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><em>H. paraphrohaemolyticus</em></td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><em>H. ducreyi</em></td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td><em>H. sputorum</em></td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

*H. aegyptius* is indistinguishable from *H. influenzae* biotype III in normal laboratory tests.

Adapted from MacFaddin¹
Appendix: X and V Factor Test

Isolate discrete colony

Light suspension of the test organism by emulsifying in normal saline

Soak a swab in the suspension

Spread evenly across the entire surface of a nutrient agar plate

Position X, V, and XV discs on the agar surface

Incubate in 3-5% CO₂ at 35-37°C overnight

Examine for areas of growth

Note:

X and V factor  Haemophilus influenzae NCTC 11931
V factor only  Haemophilus parainfluenzae NCTC 10665
X factor only  Haemophilus haemoglobinophilus  NCTC 8540

The flowchart is for guidance only.
References


3. European Parliament. UK Standards for Microbiology Investigations (SMIs) use the term "CE marked leak proof container" to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: "The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes".


